Renovaro Inc. (NASDAQ:RENB - Get Free Report) shares fell 1.3% during mid-day trading on Monday . The company traded as low as $0.28 and last traded at $0.29. 1,789,053 shares changed hands during trading, an increase of 15% from the average session volume of 1,559,300 shares. The stock had previously closed at $0.29.
Renovaro Price Performance
The stock has a fifty day moving average price of $0.33 and a 200-day moving average price of $0.61.
Hedge Funds Weigh In On Renovaro
A number of institutional investors have recently bought and sold shares of RENB. ProShare Advisors LLC acquired a new stake in shares of Renovaro in the fourth quarter worth $27,000. Voya Investment Management LLC purchased a new stake in Renovaro in the fourth quarter valued at $30,000. The Manufacturers Life Insurance Company acquired a new stake in Renovaro during the 4th quarter worth about $38,000. Price T Rowe Associates Inc. MD raised its stake in shares of Renovaro by 183.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 45,198 shares of the company's stock valued at $38,000 after buying an additional 29,253 shares during the last quarter. Finally, Corebridge Financial Inc. lifted its holdings in shares of Renovaro by 114.8% in the 4th quarter. Corebridge Financial Inc. now owns 57,495 shares of the company's stock valued at $48,000 after buying an additional 30,727 shares during the period. 71.41% of the stock is owned by hedge funds and other institutional investors.
Renovaro Company Profile
(
Get Free Report)
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Recommended Stories
Before you consider Renovaro, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Renovaro wasn't on the list.
While Renovaro currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
